Vincristine sulfate

Catalog No.S1241 Synonyms: Leurocristine

Vincristine sulfate Chemical Structure

Molecular Weight(MW): 923.04

Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.

Size Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

2 Customer Reviews

  • Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

    Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

    for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent  experiments and of f our replicates in each experiment.

    Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro

Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2.2.15 NV7lT|RlS2WubDDWbYFjcWyrdImgRZN{[Xl? M4LiSlAuOC53IN88US=> NGj6enMzPCCq NWjkcYlY\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm= NETrTIozPTZ4M{e2PS=>
HepG2-HBV1.1 NHPnbZRCeG:ydH;zbZMhSXO|YYm= NVO2blFxOC1yLkWg{txO Mk\HNlQhcA>? NH;GRZBqdmS3Y3XzJIFxd3C2b4Ppd{Bld3OnIHTldIVv\GWwdHz5 NGLKPWszPTZ4M{e2PS=>
HepG2.2.15 M{XpbGZ2dmO2aX;uJGF{e2G7 NIj3[lQxNjFizszN M4DzdlI1KGh? M3W0c5Bzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW|c3nvci=> MWCyOVY3Ozd4OR?=
HepG2-HBV1.1 NFLxUnNHfW6ldHnvckBCe3OjeR?= NFG1V3oxNjFizszN M1TTdlI1KGh? MYHwdo9ud3SnczDo[ZBifGm2aYOgRkB3cXK3czDwdo91\WmwIHX4dJJme3Orb36= M3jFOFI2PjZ|N{[5
HepG2-HBV1.1 M3rJPGZ2dmO2aX;uJGF{e2G7 MkfNNE4yKM7:TR?= M1voNlQ5KGh? MnLGdJJwdW:2ZYOgZ4VtdCCneHPy[ZRqd25ib3[gbIVx[XSrdHnzJGIhfmm{dYOgcpVkdGWxY3Hwd4lleyCrboP0[YFlKG:oIHjldIF1cXSrczDCJJZqenW|IFThcoUheGG{dHnjcIV{ MnTFNlU3PjN5Nkm=
HepG2-HBV1.1 M4\pPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXxeIplOC5zIN88US=> MkS4NU02KGR? NV\lVYVmcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=> NV;VOWhCOjV4NkO3Olk>
HepG2-HBV1.1 NGrXVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXXVpE{OC5zIN88US=> MmfHNU02KGR? Mn;abY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36geIlu\SCmZYDlcoRmdnSueR?= MV[yOVY3Ozd4OR?=
HepG2-HBV1.1 NWX4[VBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWqwMlEh|ryP MmXlNVIuPzJiaB?= M1LYfIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=> M{XrbVI2PjZ|N{[5
HepG2-HBV1.1 M1TxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jMR|AvOSEQvF2= MmnGNVIuPzJiaB?= MnuxbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBUNXCqYYPl NYDOU2hiOjV4NkO3Olk>
Raji M1Pqc2Z2dmO2aX;uJGF{e2G7 MW[wMlXDqM7:TR?= NHv5c2Y4OiCq MnnNZYJwdGm|aHXzJIF2fG:yaHHnfeKh MorVNlU1PDZ|N{e=
SK-MEL-28  M1\kd2Z2dmO2aX;uJGF{e2G7 MYmzNEBvVQ>? MmXZOkBp MXvpcoR2[2W|IFey5qCUVSClZXzsMYN6[2ynIHHydoV{fA>? MXWyOVMyOzBzMB?=
H157 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTTNo1KSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?= NHixT2gzPTJ3N{mxNS=>
Jurkat NFTPd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf1PGQyNTNibl2= MofXOFjDqGh? M1vIdGROW09? NV7mUIpq\GWlcnXhd4V{KH[rYXLs[UBk\WyuIH71cYJmenNiZH;z[UBl\XCnbnTlcpRtgQ>? MV:yOVE2PjF2Nh?=
CEM NXq5VZNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkniNU0{KG6P MkToOFjDqGh? NVO4UFQyTE2VTx?= Mn[x[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:|ZTDk[ZBmdmSnboTsfS=> M3XnOVI2OTV4MUS2
P12 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13mN|EuOyCwTR?= MnLjOFjDqGh? MmHtSG1UVw>? NFvIOIll\WO{ZXHz[ZMhfmmjYnzlJINmdGxiboXtZoVzeyCmb4PlJIRmeGWwZHXueIx6 MUmyOVE2PjF2Nh?=
KB NGi3UHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXuNHNKSzVyPUCuNFA1QSEEsTCwMlAxODFizszN NHnRdlkzPTB3OEWyOi=>
KBv200 (ABCB1) NHjEcZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTb3RyUUN3ME2wMlM1PjJiwsGgNE4xODZ4IN88US=> MoTjNlUxPTh3Mk[=
SUDHL6  MlPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6x5qCK|ryP M3XPTVQ5Nzd{IHi= M3;1OolvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MV:yOFk3OTZyNB?=
SUDHL6  M{[4V2Z2dmO2aX;uJGF{e2G7 NYnrZYplOeLCid88US=> MX23NkBp NX3MeWJ5cW6mdXPld{B{cWewaX\pZ4FvfCCjcH;weI91cWNibX;ydIhwdG:peTDjbIFv\2W|IHPveJJme3SnZDD3bZRpKEKFTEGxRUB{cVKQQR?= MmDjNlQ6PjF4MES=
HCT-116 M3TuN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXG2[257T0l3ME21JI5O M3HSblI1QTJ5OEW3
SKNBe2C NXPU[Id6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLWUplKSzVyPUOyMljDuTRwMDDuUS=> MlLONlQ6OjF7MkC=
IGNR91 M4rYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTJ2LkRCtVEvPyCwTR?= NEPpd|gzPDl{MUmyNC=>
SKNAS NXywXm9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzWbXFKSzVyPUGuOeKyOC5{IH7N NIfGepMzPDl{MUmyNC=>
LAN1 NVPyZlRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\IPGlEPTB;Mj6zxtExNjJibl2= M{mySFI1QTJzOUKw
SHSY5Y MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjCb4xKSzVyPUiuNuKyOC54IH7N NIjaWI8zPDl{MUmyNC=>
A549-WT NVXBdWFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTF7LkSzO{DDuSByLkW5OEAhdk1? MVOyOFg2QDh{Nx?=
A549-R NW\jXHdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF{LkG3PEDDuSByLkOzN{Ahdk1? NFLSeJQzPDh3OEiyOy=>
MCF-7-WT NUPOXVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTF5Lke1NkDDuSByLkKxPEAhdk1? MknqNlQ5PTh6Mke=
MCF-7-R MknTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PFV2lEPTB;NT61N|khyrFiMD6xOFQhKG6P M3PmN|I1QDV6OEK3
A549-R NXn4ZlltS3m2b4TvfIlkcXS7IFHzd4F6 NV;CXIU3UUN3ME2xNk4yPzhiwsGgNE4{OzNibl2= NUH1Wm1oOjR6NUi4Nlc>
MCF-7-R NEXaUmVEgXSxdH;4bYNqfHliQYPzZZk> M2XxXmlEPTB;NT61N|khyrFiMD6xOFQhdk1? MnS0NlQ5PTh6Mke=
SW620 M3Xhb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mny4TWM2OD15LkiwJOKyKDBwMEigcm0> NVTiZYlUOjR5Mk[3N|k>
SW620/AD300 M3;jXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjaNlBmUUN3ME25NFkvPjBiwsGgPE46OSCwTR?= NX3GR|JZOjR5Mk[3N|k>
HEK293/pcDNA3.1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTFwNEWgxtEhOC5{MDDuUS=> MoXlNlQ4OjZ5M{m=
HEK293/ABCC1 M17HfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF7LkK5JOKyKDJwMEigcm0> M2Pq[FI1PzJ4N{O5
TCC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPUNlQhcA>? NV3UTYxjUUN3ME23NEBvVQ>? M17OUVI1PzF4OUS0
TCC M1u3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LLO|Q5KGh? Mo\yTWM2OD13MDDuUS=> MVWyOFcyPjl2NB?=
HepG2/ADM NIPId4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvzenVSUUN3ME2yMlc5PjQEsUCuNlM4OSEQvF2= M1nwdVI1PzB2NUW2
HepG2 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHyTWM2OD1yLkCxNVXDuTBwMECxO{DPxE1? M2rmSlI1PzB2NUW2
MCF-7/ADR NVH0O29uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwNEiyOuKyOC5{MEewJO69VQ>? NYjqfJVxOjR5MES1OVY>
MCF-7 NV;SfZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMEG1PeKyOC5yME[yJO69VQ>? MXuyOFcxPDV3Nh?=
A-172  MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fnWFAvOcLizszN MofxNlQwPzJiaB?= NIL2cYxqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lJIRmeGWwZHXueIx6 MXKyOFU{ODJ|NR?=
U-251MG NHvPepZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPiNE4yyqEQvF2= NV7kVHZ3OjRxN{KgbC=> Mn7EbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=> NH;KRoszPDV|MEKzOS=>
DLD-1 M3fWNmZ2dmO2aX;uJGF{e2G7 MlzFNVAxKG6P MYe0PEBp MYrwdo9ud3SnczDSWW5ZOyCmZX3leIh6dGG2aX;uxsA> M1L2V|I1PDB|NEWz
CCD18Co MUXGeY5kfGmxbjDBd5NigQ>? M2XkZVExOCCwTR?= M33Xd|Q5KGh? MlWxdJJwdW:2ZYOgVnVPYDNiZHXt[ZRpgWyjdHnvcuKh NVmwRlJWOjR2MEO0OVM>
DLD-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T2cFAuOTByMDDuUS=> NV\sdZRPPDhiaB?= MlrmbY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> MWmyOFQxOzR3Mx?=
CCD18Co MnnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWRWcxNTFyMECgcm0> M33rOlQ5KGh? NWXJU|FjcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MmHpNlQ1ODN2NUO=
HepG2 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\XS45zOjRiaB?= M1jyV2lEPTB;NUKuOgKBkc7:TR?= NYPFWJNzOjR|NEG2PFg>
HEK293/pcDNA3.1 M1zzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zP[WlEPTB;MD6wNFTDuTBwMECwN{DPxE1? MVqyOFI5PDd6Mx?=
HEK293/MRP1 M3LLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHyydI9KSzVyPUCuNFU2yrFyLkCxNlAh|ryP NV\ZfXhiOjR{OES3PFM>
Ramos M1XzS2Fxd3C2b4Ppd{BCe3OjeR?= NX[yeIRoOuLCid88US=> NGPXe|c1QCCq M{j3VIlv\HWlZYOgN|QvPiYEsUGuPVImKGGyb4D0c5Nqew>? MnHINlQzPTZ2OUG=
NCI-H1299/pcDNA3 NE\YN3BE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWiwMVIxKG6P M4HB[Fk3KGh? MoftbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4HSb|I1OTd5MEGy
H1299/ICAM-3 NWLOSFAzS2WubDDWbYFjcWyrdImgRZN{[Xl? MUWwMVIxKG6P NXjxWlRjQTZiaB?= NVfo[VNjcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M33ufFI1OTd5MEGy
NCI-H1299/pcDNA3 NWnQXFF2TnWwY4Tpc44hSXO|YYm= MlixNU82NzFyL{KwxsBvVQ>? M1:1Nlk3KGh? NEjqWnFqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR MWSyOFE4PzBzMh?=
H1299/ICAM-3 M2\6eGZ2dmO2aX;uJGF{e2G7 M{PtZlEwPS9zMD:yNOKhdk1? M1GyVVk3KGh? NWPwSYM6cW6mdXPld{BkdGWjdnHn[UBw\iClYYPwZZNmey1|LDC4MEA6NCCjbnSgVGFTWA>? M{jDelI1OTd5MEGy
W1 NHzOOFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMECzNkDPxE1? MX6yOFE1ODF5Nh?=
W1VR M3TFV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrOUZpKSzVyPUCuNFU3KM7:TR?= M2DXT|I1OTRyMUe2
K562 NIjURnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXnTWM2OD1yLkCzNkDDuSByLkCwNUAh|ryP Mnf2NlQyOzV7M{e=
K562/ADR NYjPSXRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3X3bGlEPTB;Mz6yOlEhyrFiMD60NVIh|ryP NFjpSG8zPDF|NUmzOy=>
K562 NFP2cpFCeG:ydH;zbZMhSXO|YYm= MnzLNE4{KM7:TR?= NVzzZWNIOjRiaB?= MWfpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 M3;SSVI1OTN3OUO3
K562/ADR M1jzeGFxd3C2b4Ppd{BCe3OjeR?= MUWzJO69VQ>? M3HF[VI1KGh? MUfpcoR2[2W|IHHwc5B1d3Orcx?= NYLEXohDOjRzM{W5N|c>
A549 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v3UWlEPTB;MD6xNEDDuSByLkCzJO69VQ>? M1\ISlI{QTdzMEe1
K562 Mlu4R4VtdCCYaXHibYxqfHliQYPzZZk> Mm\hN{44PeLCk{[wxsBvVQ>? M2DGWlczyqCqwrC= NYjOSXB7cW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= NV;Z[Vl{OjN6N{eyNlM>
lucena NWLOZYhlS2WubDDWbYFjcWyrdImgRZN{[Xl? MmKxN{44PeLCk{[wxsBvVQ>? MmTpO|LDqGkEoB?= MorQco8h\W[oZXP0 MWeyN|g4PzJ{Mx?=
FEPS MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4L4VlMvPzYkgKO2NOKhdk1? NYPRR2F3PzMEoHlCpC=> M3fXb45wKGWoZnXjeC=> MVKyN|g4PzJ{Mx?=
A2780 NGrrT4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTNwNTDtUS=> MV6yN|gzQTJyMx?=
ACHN NYH1bVY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjOZplXUUN3MEywMlEhdU1? NYG5dIJqOjN6MkmyNFM>
U-937 MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLi[FltUUN3MEyzOEBvVQ>? M3n3R|I{QDJ7MkCz
Jurkat NULzeG1VSXCxcITvd4l{KEG|c3H5 NHXqUYY2yqEQvHevcYzDqA>? MWiyOEBp NUfHXYlUcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?= MYSyN|gyODRyOR?=
Jurkat M2DxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXWFXDqM7:Zz;tcOKh MV6yOEBp MXrhdpJme3RiSoXyb4F1KGOnbHzzJIlvKEd{L12gdIhie2V? M4LYcFI{QDFyNEC5
Hep-2 NWHYXZJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGxTWM2OD1yLkC0xtExNjBzIN88US=> M3\Qc|I{PzhyNEK0
Hep-2/v MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TETmlEPTB;MT64xtExNjJyIN88US=> NVTRXml6OjN5OEC0NlQ>
SGC-7901 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV2wMVExKM7:Zz;tcC=> NXTJfopzOjRxNEivO|IhcA>? MXjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= NFO4UG8zOzd2M{W3Ni=>
SGC-7901/VCR NUjLUI12T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M370dVAuOTBizsznM41t MoC5NlQwPDhxN{KgbC=> M1XGXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NHPJ[JYzOzd2M{W3Ni=>
SGC-7901 NWewfYw6SXCxcITvd4l{KEG|c3H5 NGC1cHpqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 Mlv1NlM4PDN3N{K=
SGC-7901/VCR NGX0eWZCeG:ydH;zbZMhSXO|YYm= MXjpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6 NIjIPVAzOzd2M{W3Ni=>
KB-3-1 NYDhbVZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXWTWM2OD1zLk[2JOKyKDBwMU[yJO69VQ>? NXnLd4VsOjN4N{O0OFU>
KB-C2 Mk\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTJyMj61OkDDuSB2Mj60PFEh|ryP MUWyN|Y4OzR2NR?=
KB-3-1 NIDMe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF75WXJKSzVyPUGuNlYhyrFiMD6wNlch|ryP MYKyN|Y4OzR2NR?=
KB-V1 NHmxRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvzdphKSzVyPUKwPE45PSEEsTCyNE41KM7:TR?= MnK1NlM3PzN2NEW=
HEK293/pcDNA3.1 NUi0cYhiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInSd21KSzVyPUK0MlEhyrFiMD6yNFQh|ryP MYSyN|Y4OzR2NR?=
HEK293/ABCB1 M4PUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHj[2hZUUN3ME2zOVEzNjhiwsGgN|c5NjN7MTFOwG0> MorLNlM3PzN2NEW=
A549/EGFP  MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLBVHIxNjBzLUGwNFAh|ryP NILOTXlKSzVyPUi2MlchyrFiMkmuNUDPxE1? M4e5cFI{PjN2Mkiy
A549/Slug NY\vZWNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vRb|AvODFvMUCwNEDPxE1? NWDUXYkxUUN3ME25MlchyrFiMz6xJO69VQ>? NGXsVmMzOzZ|NEK4Ni=>
JFCR39  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi0NXc6OSEEtV2= NGPEUmIzPCCq MWXEUXNQ MmfXcYFzc2WmbImgbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiR{KvUUBxcGG|ZTDj[Yxtew>? NXviU5VTOjN3OUiyO|Y>
A549 NYTBXWxjTnWwY4Tpc44hSXO|YYm= MX6xNFAhdk1? M4fwRVE3KGh? MnnnSG1UVw>? NV3IZ2d3dGWjZIOgeI8h[SCub4PzJI9nKG2rY4LveJVjfWyncx?= MWqyN|U6QDJ5Nh?=
SGC7901 NFLpVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3tTWM2OD1zLkK25qCKyrIkgJmwMlEyKM7:Zz;tcC=> M2nUXlI{PTZ2NEiy
SGC7901/LV-NC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfheHNsUUN3ME2xMlc46oDLwsJihKkxNjF4IN88[{9udA>? Mmm2NlM2PjR2OEK=
SGC7901/LV-SGO1 NH75WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HWW2lEPTB;ND6zOwKBkcLz4pEJNE4{PyEQvHevcYw> M1v3TlI{PTZ2NEiy
SGC7901/VCR MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XRW2lEPTN;MkCuOVPjiIoEsfMAjVEvQTZizsznM41t NVi3e5dOOjN3NkS0PFI>
SGC7901/VCR-NC M4DJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:3TWM2OD1zOT64OwKBkcLz4pEJNk4xOSEQvHevcYw> M1zKfVI{PTZ2NEiy
SGC7901/VCR-si-SGO1 MonxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTZwMUlihKnDueLCiUGuNFMh|rypL33s MX:yN|U3PDR6Mh?=
SGC7901/ADR M2m0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zEdmlEPTB;Nz64OgKBkcLz4pEJNE43PCEQvHevcYw> NUKyXo1GOjN3NkS0PFI>
SGC7901/ADR-NC M17QSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;BNZZKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t NFjzVmEzOzV4NES4Ni=>
SGC7901/ADR-si-SGO1 NF7YdHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfJbo5KSzVyPUOuOFbjiIoEsfMAjVAvOjlizsznM41t MWGyN|U3PDR6Mh?=
SH-SY5Y  M1S1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYmwMlAxOS1zMDFOwG0> MofsNlQhcA>? NIf2OWNKSzVyPUCuNVE{yrFyLkCxNkDPxE1? Mn2yNlMyOjlyNkW=
SH-SY5Y  NUjvWWlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFi3S4UxNjByMT2xNEDPxE1? NWTuPWdsPDhiaB?= M4D5V2lEPTB;MD6wO|jDuTBwMEC5JO69VQ>? MVSyN|EzQTB4NR?=
SH-SY5Y  M3jl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZTnVjOC5yMEGtNVAh|ryP M1HZelczKGh? NUHX[21GUUN3ME2wMlA2OcLzMD6wNFgh|ryP MYCyN|EzQTB4NR?=
SH-SY5Y NVLvVoZvSXCxcITvd4l{KEG|c3H5 MWewMlEh|ryP MYewMVI1KGh? Mo[3bY5lfWOnczDhdI9xfG:|aYOgc4YhW0hvU2m1XUBk\WyuczDmc4xtd3erbnegZ4VtdCCleXPs[UBienKnc4SgZZQhfGinIFeyM20heGijc3W= M{fIXFI{OTJ7ME[1
SH-SY5Y M2LBSGFxd3C2b4Ppd{BCe3OjeR?= MYSwMlEh|ryP NWrFb3NGOC1{NDDo NYrheHU3cW6mdXPld{BucXSxdHnjJIFzemW|dNMg MlHhNlMyOjlyNkW=

... Click to View More Cell Line Experimental Data

In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol

Cell Research
+ Expand
  • Cell lines: B16 melanoma cell
  • Concentrations: 10 nM
  • Incubation Time: 3 days
  • Method: Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Human rhabdomyosarcoma xenografts Rh12
  • Formulation: Water solutioin
  • Dosages: 3 mg/kg
  • Administration: A single i.p. administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (108.33 mM)
Water 60 mg/mL (65.0 mM)
Ethanol <1 mg/mL
In vivo Saline 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 923.04
Formula

C46H58N4O14S

CAS No. 2068-78-2
Storage powder
in solvent
Synonyms Leurocristine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02828358 Not yet recruiting Acute Leukemia of Ambiguous Lineage|Childhood B Acute Lymphoblastic Leukemia|Mixed Phenotype Acute Leukemia National Cancer Institute (NCI) December 2016 --
NCT02724579 Not yet recruiting Untreated Childhood Medulloblastoma Childrens Oncology Group|National Cancer Institute (NCI) October 2016 Phase 2
NCT01775475 Not yet recruiting AIDS-related Diffuse Large Cell Lymphoma|AIDS-related Diffuse Mixed Cell Lymphoma|AIDS-related Diffuse Small Cleaved Cell Lymphoma|AIDS-related Immunoblastic Large Cell Lymphoma|AIDS-related Lymphoblastic Lymphoma|AIDS-related Peripheral/Systemic Lymphoma|AIDS-related Small Noncleaved Cell Lymphoma|Stage III AIDS-related Lymphoma|Stage IV AIDS-related Lymphoma AIDS Malignancy Consortium|National Cancer Institute (NCI)|The EMMES Corporation September 2016 Phase 2
NCT02257242 Not yet recruiting Lymphoma, Non-Hodgkin|Lymphoma, Follicular|Lymphoma, Mantle-Cell|Lymphoma, Small-Cell|Waldenstrom Macroglobulinemia|Lymphoma, B-Cell, Marginal Zone Adam Olszewski|Spectrum Pharmaceuticals, Inc|Rhode Island Hospital|The Miriam Hospital|Brown University September 2016 Phase 1
NCT02723994 Not yet recruiting B-cell Acute Lymphoblastic Leukemia Incyte Corporation|Childrens Oncology Group August 2016 Phase 2
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) August 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?

  • Answer:

    According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Vincristine sulfate | Vincristine sulfate supplier | purchase Vincristine sulfate | Vincristine sulfate cost | Vincristine sulfate manufacturer | order Vincristine sulfate | Vincristine sulfate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID